Home » News » Drug Sponsors » Depomed rejects new Horizon Pharma proposal

Depomed rejects new Horizon Pharma proposal

Thursday, August 20, 2015

Depomed’s board of directors has unanimously rejected Horizon Pharma’s revised all-stock proposal.

On Aug. 13, Horizon revised its previous proposal and set an exchange ratio of 0.95 of Horizon shares for each share of Depomed, and offered to include up to 25% in cash subject to a reduction in the total consideration per share. Depomed officials said the new proposal has a current value below $30 per share, which is less than the $33 per share proposal Horizon previously made, and represents ownership in the combined company of less than 29%. The company believes that figure is well below what Depomed would contribute to the combined company.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!